Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Pain 1Neoplasm, Residual 1Multiple Myeloma 1Dwarfism, Pituitary 1Disease Progression 1Breast Neoplasms 1Bone Diseases, Metabolic 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Calcium × Clear all
NCT00171925 2012-04-11

Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

Novartis

Phase 3 Terminated
143 enrolled 10 charts
Plasma cell

Multiple Myeloma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡